Provided by Tiger Trade Technology Pte. Ltd.

Indaptus Therapeutics, Inc.

2.14
-0.0700-3.17%
Volume:23.62K
Turnover:50.88K
Market Cap:3.75M
PE:-0.08
High:2.23
Open:2.23
Low:2.09
Close:2.21
52wk High:47.60
52wk Low:1.65
Shares:1.75M
Float Shares:850.70K
Volume Ratio:1.54
T/O Rate:2.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.4525
EPS(LYR):-44.9582
ROE:-317.98%
ROA:-131.38%
PB:0.81
PE(LYR):-0.05

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)

TIPRANKS
·
Nov 14

Indaptus Therapeutics Q3 profit beats estimates

Reuters
·
Nov 12

Indaptus Therapeutics posts third quarter net loss of $2.98 per share

Reuters
·
Nov 12

Rpt-Indaptus Therapeutics Q3 EPS USD -2.98

THOMSON REUTERS
·
Nov 12

Investors Await Key Jobs Data as US Futures Mixed in Friday's Premarket

MT Newswires Live
·
Sep 05

Indaptus Therapeutics Announces Promising Updates on Decoy20 and Tislelizumab Combination Therapy in Ongoing Clinical Trial

Reuters
·
Sep 05

Indaptus Therapeutics Inc - Decoy20 Monotherapy Induces Partial Response in Cancer Patient

THOMSON REUTERS
·
Sep 05

Indaptus Therapeutics Inc - Decoy20 Combination With Pd-1 Inhibitor Shows Consistent Safety

THOMSON REUTERS
·
Sep 05

Indaptus Therapeutics: Files for Mixed Shelf Offering of up to $200 Mln- SEC Filing

THOMSON REUTERS
·
Aug 14

Rpt- Indaptus Therapeutics Inc Q2 EPS $-9.09

THOMSON REUTERS
·
Aug 13

Indaptus Therapeutics Q2 EPS $(9.09) Beats $(9.24) Estimate

Benzinga
·
Aug 13

Indaptus Therapeutics Initiates Phase 1b/2 Trial Combining Decoy20 With PD-1 Inhibitor Tislelizumab for Cancer Treatment

Reuters
·
Aug 13

Indaptus Therapeutics Inc. Held Special Meeting of Shareholders

Reuters
·
Jul 30

Indaptus Therapeutics Raises $3.4 Million in Additional Private Placement of Convertible Notes and Warrants

Reuters
·
Jul 01

BRIEF-Indaptus Therapeutics Announces Reverse Stock Split

Reuters
·
Jun 25

Indaptus Therapeutics Sells $2.3 Million of Convertible Notes, Warrants; Shares Fall Pre-Bell

MT Newswires Live
·
Jun 13

Indaptus Therapeutics Inc. Conducted Annual Meeting

Reuters
·
Jun 12